This study was designed to investigate whether the L/N-type calcium channel blocker, cilnidipine, had a renoprotective effect compared with other calcium channel blockers. Twenty-five hypertensive patients with concomitant type 2 diabetes who had a urinary albumin-creatinine ratio (ACR) of 10 -300 mg albumin/g creatinine and who had been treated with oral calcium channel blockers other than cilnidipine for more than 3 months were included. Patients' medication was changed to cilnidipine 10 mg/day or 20 mg/day without a washout period. Blood pressure and renal function were measured before and at 3 months after the new treatment. Heart rate was also determined as a marker for sympathetic nervous activity. After substitution of cilnidipine, blood pressure did not change significantly, but heart rate decreased significantly from 73.9 ± 7.1 beats/min to 72.0 ± 8.4 beats/min, and the log-transformed urinary ACR decreased to 82.9 ± 49.4% of baseline values. The changes in urinary ACR and heart rate showed a significant positive correlation. Thus, there was a strong indication that cilnidipine may exert its renoprotective effect by inhibiting sympathetic nervous activity.
Introduction
It has frequently been reported that calcium channel blockers are inferior to angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in terms of renal protection. 1 -3 In addition, most L-type calcium channel blockers dilate only renal afferent arterioles and are prone to causing glomerular hypertension. It has been reported that cilnidipine, a L/N-type calcium channel blocker, inhibits sympathetic nervous activity by blocking Ntype calcium channels and dilating renal afferent and efferent arterioles equally, showing a renoprotective effect. 4,5 Compared with other calcium channel blockers, this drug reduces urinary albumin and protein excretion to a greater extent; 6,7 it has a urinary protein-lowering effect equivalent to ACEIs, 8 and its combination with an ARB further reduces albuminuria. 9 Few studies have examined whether M Tanaka Renoprotective effects of cilnidipine in type 2 diabetes switching from other calcium channel blockers to cilnidipine can decrease urinary protein and albuminuria. It has been reported that changing from manidipine, diltiazem or nisoldipine to cilnidipine decreased urinary protein excretion. 10 The effect on microalbuminuria, however, remains unclear.
The present study was, therefore, designed to examine whether switching from other calcium channel blockers to cilnidipine could have renoprotective effects in hypertensive patients with concomitant diabetes and albuminuria. Heart rate was also measured, as an indicator of possible effects on sympathetic nervous activity.
Patients and methods

PATIENTS AND STUDY DESIGN
Hypertensive patients with concomitant type 2 diabetes who were being treated as outpatients at the Department of Endocrinology, Tenri Hospital, Tenri, Nara, Japan, were enrolled sequentially into the study between April and November 2007. All patients had to have a urinary albumincreatinine ratio (ACR) of 10 -300 mg/g creatinine, and had to have been treated with oral calcium channel blockers other than cilnidipine for more than 3 months. Patients' calcium channel blocker medication was changed from their existing calcium channel blocker medication to either 10 mg/day or 20 mg/day of cilnidipine without a washout period.
The study protocol was approved by the Ethics Committee of the Tenri Hospital, Tenri, Nara, Japan. Written informed consent was obtained from all the study participants.
PATIENT ASSESSMENT
Blood pressure and renal function parameters (blood urea nitrogen, creatinine and ACR) were measured before and 3 months after switching to cilnidipine. Blood pressure measurement was carried out according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension. 11 The ACR was measured using the first urine sample of the morning. In addition, heart rate was measured, as an indicator of sympathetic nervous activity, by palpation at the radial artery for 1 min after a few minutes' rest.
Drug safety was monitored by measuring body weight, hepatic function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, γ-glutamyl transferase, and alkaline phosphatase), glucose metabolism (glycosylated haemoglobin A 1c ), serum lipids (low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, and triglycerides), uric acid and electrolytes (Na + , K + ) before and 3 months after changing to cilnidipine.
STATISTICAL ANALYSIS
Results were expressed as mean values ± SD. Data analyses were performed using the JMP ® software package, version 6 (SAS Japan Institute Ltd, Tokyo, Japan) for Windows ® . A paired t-test was used to assess significant differences between values obtained before and 3 months after the change of drug treatment. As the ACR data showed a skewed distribution, raw values were logtransformed and the percentage change from baseline was calculated. Any relationship between the change in urinary ACR and heart rate was examined using the Pearson product-moment correlation coefficient. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENT CHARACTERISTICS
A total of 25 hypertensive patients with concomitant type 2 diabetes were included in the study. Their characteristics are M Tanaka Renoprotective effects of cilnidipine in type 2 diabetes summarized in Table 1 . Of the 25 patients, 21 were concomitantly taking a calcium channel blocker and an ARB and two patients were taking a calcium channel blocker and ACEIs as antihypertensive drugs. None of the patients was simultaneously taking a calcium channel blocker, an ARB and an ACEI. At study entry, the following calcium channel blockers were being taken: 5 mg/day amlodipine (n = 10), 4 mg/day benidipine (n = 6), 8 mg/day benidipine (n = 2), 8 mg/day azelnidipine (n = 1), 16 mg/day azelnidipine (n = 2), 20 mg/day nifedipine (n = 1), 15 mg/day barnidipine (n = 1), 20 mg/day manidipine (n = 1) and 20 mg/day efonidipine (n = 1). Patients were switched from their current calcium channel blocker medication to receive either 10 mg/day cilnidipine (n = 14) or 20 mg/day cilnidipine (n = 11).
TABLE 1: Baseline characteristics of the hypertensive patients with concomitant type 2 diabetes who had been treated with oral calcium channel blockers other than cilnidipine for more than 3 months and were enrolled into the study (n = 25)
Gender, 
M Tanaka Renoprotective effects of cilnidipine in type 2 diabetes BLOOD PRESSURE AND HEART RATE
Compared with baseline, at 3 months after switching from other calcium channel blockers to cilnidipine, the systolic (144.8 ± 15.1 mmHg and 140.3 ± 13.5 mmHg, respectively) and diastolic (76.2 ± 10.1 mmHg and 72.9 ± 10.2 mmHg, respectively) blood pressures had not changed significantly. The heart rate, however, decreased significantly from 73.9 ± 7.1 beats/min to 72.0 ± 8.4 beats/min (P < 0.05) ( Fig. 1 ).
MICROALBUMINURIA AND CORRELATION WITH HEART RATE
At 3 months after switching from other calcium channel blockers to cilnidipine, the urinary ACR had decreased to a mean ± SD of 82.9 ± 49.4% of the baseline value (P < 0.05) (Fig. 2) .
There was also a significant positive correlation between the change in urinary ACR and the change in heart rate (before minus after the switch in medication) (r = 0.521, P = 0.018) (Fig. 3) . The numbers of patients with albuminuria < 30 mg/g creatinine were five (20%) before and 10 (40%) after switching from other calcium channel blockers to cilnidipine.
DRUG SAFETY
There were no significant differences in body weight, blood urea nitrogen, creatinine, hepatic function, glycosylated haemoglobin A 1c , serum lipids, uric acid, Na + and K + after switching from other calcium channel blockers to cilnidipine ( Table 2) . No adverse events were reported except for a mild itching sensation in one patient and facial flushing in another; all patients were able to continue with oral cilnidipine treatment. 
Discussion
In the present study, switching from other calcium channel blockers to cilnidipine did not lead to a significant change in blood pressure, but heart rate was significantly decreased. This could potentially be explained by the inhibition of cardiac sympathetic nervous activity by this L/N type-calcium channel blocker. 12 It has been reported elsewhere that heart rate is significantly decreased by cilnidipine, but not by amlodipine. 13 A higher heart rate is an independent risk factor for cardiovascular death; a higher heart rate was associated with increased mortality from cardiovascular disease in the Japanese general population 14, 15 and with an increase in the total death rate and cardiovascular mortality rate in American patients with hypertension. 16 Many calcium channel blockers cause reflex tachycardia as a common side-effect; replacing these drugs with cilnidipine should decrease the heart rate, leading potentially to a reduction in the mortality of hypertensive patients with concomitant type 2 diabetes.
A significant reduction in urinary ACR was observed in the present study after switching to cilnidipine. The Japanese Society of Hypertension Guidelines for the Management of Hypertension recommend that albuminuria should be reduced to < 30 mg/g creatinine in diabetic patients. 11 In the present study, five (20%) and 10 (40%) patients achieved this target before and after switching from other medication to cilnidipine, respectively. Albuminuria has been established as an independent risk factor for cardiovascular events; it has been reported that an increase in albuminuria elevates the risk of developing cardiovascular disease and the risk of death, 17, 18 and that, in turn, a reduction in albuminuria through treatment reduces risk. 19 Values < 30 mg/g creatinine are defined as normal but it has been reported that, even at the highest normal level of albuminuria, the risk for cardiovascular events is increased. 20, 21 Thus, patients with values < 30 mg/g creatinine were included in the present study, in addition to patients with higher creatinine levels. Since no significant changes in blood pressure were observed after switching to cilnidipine, mechanisms other than a blood pressurelowering effect must have contributed to the urinary albumin-lowering effect of cilnidipine.
An important finding in the present study was the simultaneous reduction in ACR and heart rate after switching to cilnidipine, with a significant positive correlation between these reductions. This indicates that inhibition of sympathetic nervous activity might be directly involved in the reduction in albuminuria. α 1 -Adrenergic blockers have been reported to reduce glomerular arteriolar resistance 22 and urinary excretion of albumin 23 in spontaneously hypertensive rats. Moreover, the centrally acting sympatholytic agent, moxonidine, has been reported to reduce glomerulosclerosis and microalbuminuria in vitro 24 and microalbuminuria in patients with essential hypertension. 25 These findings support the hypothesis that inhibiting sympathetic nervous activity may be significant for renoprotection.
Because chronic kidney disease patients with concomitant hypertension have high sympathetic nervous activity 26 and patients with a high level of albuminuria show high values of urinary adrenaline, 27 it can be speculated that patients with hypertension complicated by renal impairment might show enhanced renal sympathetic nervous activity. In addition, it has been reported that sympathetic nervous activity is already enhanced in patients with diabetes 28 or its precursor of impaired glucose tolerance. 29 Under such circumstances, efferent arterioles are constricted and intraglomerular pressure is elevated. Because N-type calcium channels are present in sympathetic nerve terminals distributed in renal efferent arterioles as well as in afferent arterioles, it may be supposed that, after switching to cilnidipine, efferent arterioles become dilated and the intraglomerular pressure decreases. This is supported by animal experiments, 5,30 but the results of the present study suggest that this also occurs in humans.
In the present study, 21 of the 25 patients were concomitantly taking ARBs and two were concomitantly taking ACEIs; thus, almost all the patients were simultaneously using renin-angiotensin system (RAS) inhibitors. Although RAS inhibitors also dilate efferent arterioles, their mechanism differs from that of cilnidipine so an additive effect might be expected. This is likely to have contributed to the superior renoprotective effect observed in this study.
With regard to adverse effects, only mild itching and facial flushing were reported, confirming the safety of cilnidipine.
In conclusion, heart rate and albuminuria were significantly decreased following a switch from other calcium channel blockers to cilnidipine, without any significant change in blood pressure. This is a strong indication that cilnidipine might exert its renoprotective effect by inhibiting sympathetic nervous activity. Since an elevated heart rate and microalbuminuria are independent risk factors for cardiovascular events, cilnidipine may reduce the risk of such events compared with other calcium channel blockers. The effects of antihypertensive therapy on sympathetic nervous activity are particularly important in hypertensive patients with concomitant diabetic nephropathy, therefore the L/N-type calcium channel blocker, cilnidipine, may be considered useful in these patients.
